TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. The firm focuses on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. Its products include Birinapant and SHAPE. The company was founded by Yigong Shi, John M. Gill and Mark A. McKinlay in July 2001 and is headquartered in Malvern, PA.
Company profile
Ticker
TLOG
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
TLOG stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
2 Dec 16
DEF 14A
Definitive proxy
1 Dec 16
8-K
Unregistered Sales of Equity Securities
22 Nov 16
PREM14A
Preliminary proxy related to merger
22 Nov 16
25
Voluntary exchange delisting
14 Nov 16
8-K
Entry into a Material Definitive Agreement
14 Nov 16
EFFECT
Notice of effectiveness
7 Nov 16
10-Q
2016 Q3
Quarterly report
3 Nov 16
8-K
Entry into a Material Definitive Agreement
3 Nov 16
DEFA14A
Additional proxy soliciting materials
3 Nov 16
Latest ownership filings
SC 13G/A
Robins David C.
16 Feb 21
SC 13G/A
TETRALOGIC PHARMACEUTICALS Corp
15 Feb 19
3
David C. Robins
27 Jun 18
SC 13G/A
TETRALOGIC PHARMACEUTICALS Corp
19 Sep 17
SC 13G/A
TETRALOGIC PHARMACEUTICALS Corp
18 Sep 17
SC 13G/A
TETRALOGIC PHARMACEUTICALS Corp
30 Aug 17
SC 13G/A
TETRALOGIC PHARMACEUTICALS Corp
17 Aug 17
SC 13G
TETRALOGIC PHARMACEUTICALS Corp
4 Aug 17
4
Change in insider ownership
16 Nov 16
3
Initial statement of insider ownership
14 Nov 16
Institutional ownership, Q1 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 3.91 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sit Investment Associates | 3.91 k | $0.00 |